Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 2,770 shares, a drop of 45.0% from the October 15th total of 5,039 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average trading volume of 15,335 shares, the days-to-cover ratio is presently 0.2 days.
Insider Activity
In other news, CFO Lee Kalowski sold 3,972 shares of Leverage Shares 2X Long FIX Daily ETF stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the completion of the sale, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of Leverage Shares 2X Long FIX Daily ETF stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $46,334.88. Following the completion of the sale, the insider owned 127,771 shares of the company’s stock, valued at $2,115,887.76. This represents a 2.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 22,054 shares of company stock valued at $320,397 in the last 90 days.
Leverage Shares 2X Long FIX Daily ETF Price Performance
BATS:FIXX opened at $5.09 on Monday. Leverage Shares 2X Long FIX Daily ETF has a 12 month low of $3.83 and a 12 month high of $15.92. The stock has a 50 day moving average of $10.29.
About Leverage Shares 2X Long FIX Daily ETF
Homology Medicines, Inc. was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders. Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases. Homology also explored the use of its platform for gene editing and other genetic medicine applications.
Featured Stories
- Five stocks we like better than Leverage Shares 2X Long FIX Daily ETF
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Leverage Shares 2X Long FIX Daily ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leverage Shares 2X Long FIX Daily ETF and related companies with MarketBeat.com's FREE daily email newsletter.
